In a major breakthrough for pancreatic cancer treatment, a new drug called daraxonrasib has been developed to delay painful symptoms and extend survival for patients with advanced disease.
According to new data presented at the American Society of Clinical Oncology (ASCO) meeting, daraxonrasib significantly extends median survival to 13.2 months in a late-stage clinical trial.
The drug targets the 'dangerous protein' RAS, which causes tumour growth and is mutated in most pancreatic cancers.
Researchers say daraxonrasib could meaningfully improve both the length and quality of life for patients with advanced disease.
Patients taking daraxonrasib went more than nine months before cancer-related symptoms worsened, compared with less than four months among those receiving chemotherapy.
The drug is a once-daily pill, allowing patients to spend more time at home with their families instead of frequent visits to infusion centres.
